Tacrolimus
- PDF / 169,338 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 78 Downloads / 180 Views
1 S
Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura: case report In a prospective cohort study consisting of 40 patients who underwent kidney transplantation from August 2016 to September 2018, a patient [age and sex not stated] was described, who developed haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura following immunosuppressive treatment with tacrolimus [route, dosage, time to reaction onsets and outcomes not stated]. The patient underwent living-donor kidney transplantation. The patient was receiving immunosuppressant therapy with tacrolimus which was initiated three months prior to transplantation. The patient’s concomitant medications consisted of mycophenolate sodium, prednisolone and methylprednisolone. Subsequently, the patient developed haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura secondary to tacrolimus therapy. Due to these side effects, patient experienced slow graft function. Jalalonmuhali M, et al. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in 803500138 Malaysia. Transplantation Proceedings 52: 1718-1722, No. 6, Jul-Aug 2020. Available from: URL: http://doi.org/10.1016/j.transproceed.2020.02.140
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
